• In the capacity of Associate Director with the Alabama Drug Discovery Alliance – a collaboration between UAB and Southern Research - I interface with a wide range of scientists involved in the drug discovery and development process, focusing on infectious diseases, oncology and neurodegenerative disorders, among others. We have currently about 15 programs in our pipeline, ranging from assay development to phase I clinical trials. I am trained in the pharmaceutical sciences and have a broad range of publications in drug delivery, viral vector-based gene therapy as well as nanotechnology in cancer, highlighting my experience in interdisciplinary research teams. I am also a member of the IND/IDE support office at UAB, giving me regulatory expertise for investigator-initiated trials. Finally, I am the Administrative Director of the Antiviral Drug Discovery and Development Center (AD3C), an NIAID-funded Center of Excellence for Translational Research, which brings together biologists and chemists among seven different US-based institutions to find new therapies for flavi-, corona-, and alphaviruses and influenza. Based on this work I was fortunate to be selected for the William Prusoff Young Investigator Lecture Award from the International Society for Antiviral Research in 2017.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2017 Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a ModelAnnual review of pharmacology.  57:155-169. 2017
    2016 Identification of small molecule inhibitors of human cytochrome c oxidase that target chemoresistant glioma cellsJournal of Biological Chemistry.  291:24188-24199. 2016
    2016 Consortia's critical role in developing medical countermeasures for re-emerging viral infections: A USA perspectiveFuture Virology.  11:187-195. 2016
    2014 Academic Medical Product Development: An Emerging Alliance of Technology Transfer Organizations and the CTSAClinical and Translational Science.  7:456-464. 2014
    2011 The Alabama drug discovery alliance: A collaborative partnership to facilitate academic drug discoveryPharmaceutical Research.  28:1454-1459. 2011
    2011 Viruses in pharmaceutical research: Swiss army knives for the prevention and treatment of diseaseMolecular Pharmaceutics.  8:1-2. 2011
    2010 An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populationsVirology.  407:196-205. 2010
    2010 Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cellsProstate.  70:362-376. 2010
    2009 Selective transduction of mature dc in human skin and lymph nodes by cd80/cd86-targeted fiber-modified adenovirus-5/3Journal of Immunotherapy.  32:895-906. 2009
    2009 Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumorsCancer Research.  69:554-564. 2009
    2009 Limitations of Adenoviral Vector-Mediated Delivery of Gold Nanoparticles to Tumors for Hyperthermia Induction.The open nanomedicine journal.  2. 2009
    2008 Enhanced gene delivery to human primary endothelial cells using tropism-modified adenovirus vectorsOpen Gene Therapy Journal.  1:7-11. 2008
    2008 Quantum dots as multimodal photoacoustic and photothermal contrast agentsNano Letters.  8:3953-3958. 2008
    2008 Characterization of infectivity of knob-modified adenoviral vectors in gliomaCancer Biology and Therapy.  7:788-795. 2008
    2008 Characterization of infectivity of knob-modified adenoviral vectors in glioma.Cancer Biology and Therapy.  7:786-793. 2008
    2008 An adenoviral platform for selective self-assembly and targeted delivery of nanoparticlesSmall.  4:262-269. 2008
    2007 Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinomaBreast Cancer Research and Treatment.  105:157-167. 2007
    2007 Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anticarcinoembryonic antigen bispecific adapterCancer Research.  67:5354-5361. 2007
    2007 Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional woundsThe Clinical investigator.  85:481-496. 2007
    2007 Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro modelGene Therapy.  14:523-532. 2007
    2007 Thermal scalpel to target cancerExpert Review of Medical Devices.  4:131-136. 2007
    2006 Transductional targeting of adenovirus vectors for gene therapyCancer Gene Therapy.  13:830-844. 2006
    2006 Combination of viral biology and nanotechnology: new applications in nanomedicineNanomedicine: Nanotechnology, Biology and Medicine.  2:200-206. 2006
    2006 Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agentsCancer Gene Therapy.  13:606-618. 2006
    2006 Covalently linked Au nanoparticles to a viral vector: Potential for combined photothermal and gene cancer therapyNano Letters.  6:587-591. 2006
    2006 Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells.Leukemia & Lymphoma.  47:507-519. 2006
    2005 A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapyGene Therapy.  12:1696-1706. 2005
    2005 In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic modelJournal of Gene Medicine.  7:1517-1525. 2005
    2005 Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapyNanomedicine: Nanotechnology, Biology and Medicine.  1:326-345. 2005
    2005 Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model systemCancer Biology and Therapy.  4:1203-1220. 2005
    2005 Targeted therapies directed to tumor-associated antigensDrugs of the future.  30:1067-1076. 2005
    2005 Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectorsGene Therapy.  12:1042-1048. 2005
    2005 Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapyGene Therapy.  12:187-193. 2005
    2005 Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model systemBreast Cancer Research.  7:R1141-R1152. 2005
    2005 The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphomaLeukemia & Lymphoma.  46:1627-1638. 2005
    2004 Genetic Replacement of the Adenovirus Shaft Fiber Reduces Liver Tropism in Ovarian Cancer Gene TherapyHuman Gene Therapy.  15:509-518. 2004
    2004 Fluorescently labeled adenovirus with pIX-EGFP for vector detectionMolecular Imaging.  3:105-116. 2004
    2004 Transductional targeting of adenoviral cancer gene therapyCurrent Gene Therapy.  4:337-346. 2004
    2003 Comparison of E-selectin expression at mRNA and protein levels in murine models of inflammationInflammation Research.  52:512-518. 2003
    2003 Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugateBiochemical Pharmacology.  65:1729-1739. 2003
    2003 In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endotheliumPharmaceutical Research.  20:64-72. 2003
    2002 Cellular handling of a dexamethasone-anti-E-selectin immunoconjugate by activated endothelial cells: Comparison with free dexamethasonePharmaceutical Research.  19:1730-1735. 2002
    2002 Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeuticsBioconjugate Chemistry.  13:128-135. 2002
    2002 Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugateJournal of Immunology.  168:883-889. 2002


    Year Title Altmetric
    2002 Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases.  Ed. 8.  2002

    Teaching Activities

    Education And Training

  • Doctor of Philosophy in Mathematics, 2002
  • Full Name

  • Maaike Everts